Kodiak Sciences
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting th...
Latest News
3 days ago · seekingalpha.com
Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced InKodiak Sciences Inc. is up 1,857% since my November 2024 Hold upgrade; I maintain Hold as its ~$6.8 billion valuation embeds optimistic commercial expectations. Zenkuda's multi-indication BLA submission is set to begin in Q4, with standard FDA review potentially yielding approval in late 2027 or early 2028. KOD's twice-yearly diabetic retinopathy dosing is compelling, but biosimilars and established brands limit penetration; switching well-controlled patients will be difficult.
3 days ago · zacks.com
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusKOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.
4 days ago · prnewswire.com
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial ResultsPALO ALTO, Calif., Nov. 12, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2026.
5 days ago · prnewswire.com
Kodiak Sciences to Present at Three Upcoming Investor ConferencesPALO ALTO, Calif., Nov. 11, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.
29 days ago · zacks.com
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.
1 month ago · prnewswire.com
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).
2 months ago · 247wallst.com
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
2 months ago · zacks.com
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsKodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
2 months ago · fool.com
Why Kodiak Sciences Skyrocketed TodayZenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.
2 months ago · seekingalpha.com
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results TranscriptKodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove KOD